New Data Proves Effectiveness of Medtronic, Inc.'s Insertable Cardiac Monitor in Detecting AF, Most Common Heart Rhythm Disorder

MINNEAPOLIS & BERLIN--(BUSINESS WIRE)--Atrial fibrillation (AF) is the most common arrhythmia, affecting an estimated 7 million people worldwide, including 4.5 million in the European Union1,2. Data presented today as a Hot Line session at the EUROPACE 2009 congress on the XPECT clinical trial, sponsored by Medtronic, Inc. (NYSE: MDT), shows that the Medtronic Reveal® XT Insertable Cardiac Monitor (ICM) reliably identifies patients with AF (sensitivity of 96.1 percent) and correctly confirms the absence of AF in patients (negative predictive value of 97.4 percent).

MORE ON THIS TOPIC